Literature DB >> 16286875

Intracerebral hemorrhage.

Neeraj Badjatia1, Jonathan Rosand.   

Abstract

INTRODUCTION: Intracerebral hemorrhage (ICH) occurs from the rupture of small vessels into the brain parenchyma and accounts for approximately 10% of all strokes in the United States, and carries with it a significantly high morbidity and mortality.
SUMMARY: This article reviews the course and management of ICH. The most common chronic vascular diseases that lead to ICH are chronic hypertension and cerebral amyloid angiopathy. Additional factors that predispose to ICH include vascular malformations, chronic alcohol use, hypocholesterolemia, and use of anticoagulant medications. The understanding of mechanisms leading to ICH has advanced significantly, but questions regarding site predilection and timing of spontaneous hemorrhage still remain. Management in the acute setting is first focused on reducing hematoma expansion. Although no specific therapy has yet been proven effective, promising agents, particularly recombinant Factor VIIa, are on the horizon. Subsequent care is focused on controlling hemostasis, hemodynamics, and intracranial pressure in efforts to minimize secondary brain injury.
CONCLUSION: The morbidity and mortality associated with ICH remain high despite recent advances in our understanding of the clinical course of ICH. Novel preventive and acute treatment therapies are needed and may be on the horizon.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286875     DOI: 10.1097/01.nrl.0000178757.68551.26

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  23 in total

Review 1.  External ventricular drainage for intraventricular hemorrhage.

Authors:  Mahua Dey; Jennifer Jaffe; Agnieszka Stadnik; Issam A Awad
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

Review 2.  Spontaneous intracerebral and intraventricular hemorrhage: advances in minimally invasive surgery and thrombolytic evacuation, and lessons learned in recent trials.

Authors:  Mahua Dey; Agnieszka Stadnik; Issam A Awad
Journal:  Neurosurgery       Date:  2014-02       Impact factor: 4.654

3.  Critical care management of acute intracerebral hemorrhage.

Authors:  Joshua N Goldstein; Aaron J Gilson
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

4.  Geldanamycin reduced brain injury in mouse model of intracerebral hemorrhage.

Authors:  Anatol Manaenko; Nancy Fathali; Shammah Williams; Tim Lekic; John H Zhang; Jiping Tang
Journal:  Acta Neurochir Suppl       Date:  2011

Review 5.  Comparison of different preclinical models of intracerebral hemorrhage.

Authors:  Anatol Manaenko; Hank Chen; John H Zhang; Jiping Tang
Journal:  Acta Neurochir Suppl       Date:  2011

Review 6.  Intracranial hemorrhage.

Authors:  J Alfredo Caceres; Joshua N Goldstein
Journal:  Emerg Med Clin North Am       Date:  2012-08       Impact factor: 2.264

Review 7.  Intracerebral hemorrhage in mouse models: therapeutic interventions and functional recovery.

Authors:  Balachandar Kathirvelu; S Thomas Carmichael
Journal:  Metab Brain Dis       Date:  2014-05-10       Impact factor: 3.584

8.  Effect of gap junction inhibition on intracerebral hemorrhage-induced brain injury in mice.

Authors:  Anatol Manaenko; Tim Lekic; Takumi Sozen; Reiko Tsuchiyama; John H Zhang; Jiping Tang
Journal:  Neurol Res       Date:  2009-03       Impact factor: 2.448

9.  Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin.

Authors:  Da Zhi Liu; Ben Waldau; Bradley P Ander; Xinhua Zhan; Boryana Stamova; Glen C Jickling; Bruce G Lyeth; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

10.  Delayed seizures after intracerebral haemorrhage.

Authors:  Alessandro Biffi; Abbas Rattani; Christopher D Anderson; Alison M Ayres; Edip M Gurol; Steven M Greenberg; Jonathan Rosand; Anand Viswanathan
Journal:  Brain       Date:  2016-08-06       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.